Why do nipt test

Overview

NIPT (Non-Invasive Prenatal Testing) is a prenatal screening method used to assess the risk of chromosomal abnormalities in a fetus, without invasive procedures that could harm the pregnancy. Developed based on the discovery of cell-free fetal DNA (cffDNA) in maternal blood in 1997 by Dennis Lo and colleagues, NIPT became clinically available in 2011, revolutionizing prenatal care. It is primarily recommended for pregnancies at higher risk, such as those with maternal age over 35, but is increasingly offered to all pregnant individuals. The test screens for common trisomies, including Down syndrome (trisomy 21), which occurs in about 1 in 700 births in the U.S., Edwards syndrome (trisomy 18, about 1 in 5,000 births), and Patau syndrome (trisomy 13, about 1 in 16,000 births). NIPT has grown rapidly, with millions of tests performed globally since its introduction, making it a key tool in modern obstetrics for early detection and informed decision-making.

How It Works

NIPT works by analyzing cell-free fetal DNA (cffDNA) fragments that circulate in the maternal bloodstream during pregnancy. These fragments originate from the placenta and are detectable from about 10 weeks of gestation onward, comprising approximately 10-20% of the total cell-free DNA in maternal blood. The process involves drawing a blood sample from the pregnant person, which is then sent to a laboratory for high-throughput sequencing or microarray analysis. By comparing the amount of DNA from specific chromosomes (e.g., chromosome 21 for Down syndrome) to reference levels, the test can identify extra copies indicative of trisomies. For instance, an increased proportion of chromosome 21 DNA suggests trisomy 21. The analysis uses advanced bioinformatics to calculate risk scores, with results typically available within 7-14 days. NIPT is highly accurate for common trisomies but is a screening test, not diagnostic; positive results often require confirmation via invasive tests like amniocentesis or chorionic villus sampling (CVS).

Why It Matters

NIPT matters because it provides a safe, non-invasive option for early prenatal screening, reducing the need for invasive procedures that carry risks like miscarriage. By offering high accuracy—for example, detecting over 99% of Down syndrome cases—it helps pregnant individuals make informed choices about their pregnancies, such as preparing for a child with special needs or considering further testing. In real-world applications, NIPT has decreased the rate of invasive diagnostic tests by up to 50% in some regions, lowering associated complications. It also supports reproductive autonomy and early medical interventions, improving outcomes for conditions detected. However, it raises ethical considerations, such as potential for sex selection or discrimination, and is not universally accessible due to cost, which can range from $800 to $2,000 out-of-pocket in the U.S. Overall, NIPT represents a significant advance in prenatal care, balancing safety, accuracy, and patient choice.